Hostname: page-component-586b7cd67f-dlnhk Total loading time: 0 Render date: 2024-11-26T06:05:24.864Z Has data issue: false hasContentIssue false
  • English
  • Français

Which neuroleptic would psychiatrists take for themselves or their relatives?

Published online by Cambridge University Press:  16 April 2020

Tilman Steinert
Tilman Steinert*
Affiliation:
Centre of Psychiatry Weissenau, Dep. Psychiatry I, University of Ulm, Weingartshofer Street, Ravensburg-Weissenau88214, Germany
*
*Auteur correspondant. E-mail address: [email protected]
Get access

Abstract

Objective. –

Psychiatrists should be asked which neuroleptic they would prefer for themselves and their relatives in the case of first manifestation of schizophrenia.

Method. –

Questionnaires were answered by 66 psychiatrists from 13 different sites in Baden-Wuerttemberg (South West Germany). Only those were included who had treated more than 50 patients with schizophrenia within the last 5 years (n = 54).

Results. –

The psychiatrists were experienced with conventional and most of the atypical agents. Fifty-one point nine percent would take olanzapine as first line treatment, 20.4% risperidone, 13.0% quetiapine, 9.3% amisulpride, 3.7% haloperidol and 1.9% perazine. In four cases, different substances were preferred for oneself and relatives.

Conclusion. –

Most psychiatrists would not take conventional neuroleptics, though 70% of prescriptions for schizophrenic patients have been conventional neuroleptics in Germany in 2000. The preferences among atypicals correspond well with the current prescription practice in Germany.

Keywords

NeurolepticsPreferencePsychiatrists
Type
Short communication
Information
European Psychiatry , Volume 18 , Issue 1 , February 2003 , pp. 40 - 41
Copyright
Copyright © Éditions scientifiques et médicales Elsevier SAS 2003

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Fritze, JKommentar zum Arzneiverordnungsreport 2001. Psycho 2002;28:158–60.Google Scholar
Kane, J, Honigfeld, G, Singer, J, Meltzer, HClozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789–96.Google ScholarPubMed
Leucht, S, Pitschel-Walz, G, Abraham, D, Kissling, WEfficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomised controlled trials. Schizophrenia Res 1999;35:51–68.Google ScholarPubMed
Mossman, D, Lehrer, DSConventional and atypical antipsychotics and the evolving standard of care. Psychiatr Serv 2000;51:1528–35.CrossRefGoogle ScholarPubMed
Schwabe, U, Paffrath, DArzneiverordnungreport 2001. Berlin: Springer; 2001.CrossRefGoogle Scholar
Submit a response

Comments

No Comments have been published for this article.